Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 287,316,672
  • Shares Outstanding, K 2,472,392
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 22,107 M
  • EBITDA $ 27,945 M
  • 60-Month Beta 0.27
  • Price/Sales 4.45
  • Price/Cash Flow 10.25
  • Price/Book 5.52

Options Overview Details

View History
  • Implied Volatility 30.45% (+1.57%)
  • Historical Volatility 27.17%
  • IV Percentile 55%
  • IV Rank 27.62%
  • IV High 53.48% on 04/10/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 1) 2.09 (1.80%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 23,751
  • Volume Avg (30-Day) 25,490
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 598,931
  • Open Int (30-Day) 587,636
  • Expected Range 113.82 to 118.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.57
  • Number of Estimates 7
  • High Estimate 2.00
  • Low Estimate -1.63
  • Prior Year 2.22
  • Growth Rate Est. (year over year) -125.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.82 +1.84%
on 03/06/26
125.14 -7.38%
on 02/25/26
-3.33 (-2.79%)
since 02/12/26
3-Month
96.79 +19.75%
on 12/16/25
125.14 -7.38%
on 02/25/26
+15.61 (+15.56%)
since 12/12/25
52-Week
73.31 +58.11%
on 05/15/25
125.14 -7.38%
on 02/25/26
+22.56 (+24.17%)
since 03/12/25

Most Recent Stories

More News
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds

2 Dow Jones Stocks to Research Further and 1 Facing Headwinds

KO : 77.61 (-0.03%)
HON : 233.40 (-2.52%)
MRK : 115.91 (-0.26%)
3 Undervalued Names Too Cheap to Ignore

Three prominent names across the biopharma and consumer staples spaces offer the potential for value plays with room for fundamental growth as well.

CPB : 21.65 (-5.62%)
MRK : 115.91 (-0.26%)
USFD : 92.61 (+1.39%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer patients...

AZN : 192.50 (-0.42%)
ZNTL : 2.75 (-7.09%)
MRK : 115.91 (-0.26%)
APRE : 0.7650 (-2.80%)
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage disease,...

MRK : 115.91 (-0.26%)
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC whose disease progressed on or after...

MRK : 115.91 (-0.26%)
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status ...

MRK : 115.91 (-0.26%)
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

First and only immunotherapy plus antibody-drug conjugate regimen, used perioperatively, to significantly extend survival for these patients KEYNOTE-B15 is the sixth study...

MRK : 115.91 (-0.26%)
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

ACLX : 114.29 (-0.06%)
XLV : 150.16 (-1.76%)
MRK : 115.91 (-0.26%)
GILD : 145.21 (-0.54%)
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

The only JAK inhibitor approved in the U.S. for the control of pruritus associated with allergic dermatitis in dogs six months of age and older

MRK : 115.91 (-0.26%)
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral...

MRK : 115.91 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 119.21
2nd Resistance Point 117.90
1st Resistance Point 116.91
Last Price 115.91
1st Support Level 114.61
2nd Support Level 113.30
3rd Support Level 112.31

See More

52-Week High 125.14
Last Price 115.91
Fibonacci 61.8% 105.34
Fibonacci 50% 99.22
Fibonacci 38.2% 93.11
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar